The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III randomized trial of eribulin (E) with gemcitabine (G) vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937 updated design.
 
Sarmad Sadeghi
No Relationships to Disclose
 
Melissa Plets
No Relationships to Disclose
 
Primo N Lara
Research Funding - AstraZeneca (Inst); Taiho Pharmaceutical (Inst)
 
Catherine Tangen
No Relationships to Disclose
 
Stephanie A. Berg
Honoraria - Aptitude Health; MJH Life Sciences
Consulting or Advisory Role - Bristol Meyers Squibb; Eisai; Exelixis; Exelixis; Genzyme; Myovant Sciences; Pfizer; Seattle Genetics/Astellas
 
Jason R Brown
Honoraria - AstraZeneca
Speakers' Bureau - EMD Serono
Research Funding - Bicycle Therapeutics (Inst); Jounce Therapeutics (Inst); Merck (Inst); Novita Pharmaceuticals (Inst); Seagen (Inst)
 
Rick Bangs
Consulting or Advisory Role - Nonagen Bioscience
Other Relationship - Bladder Cancer Advocacy Network; National Cancer Institute; SWOG; SWOG; SWOG
(OPTIONAL) Uncompensated Relationships - Genentech; Gilead Sciences
 
Darrell Nakagawa
Leadership - Bladder Cancer Advocacy Network
Honoraria - Tyra Biosciences
 
Siamak Daneshmand
Stock and Other Ownership Interests - Taris
Honoraria - Aduro Biotech; Allergan (I); Bausch and Lomb (I); Bristol-Myers Squibb; CG Oncology; Ferring; Janssen Oncology; Johnson & Johnson; Olympus; pacific edge; Pfizer; Photocure; Protara Therapeutics; QED Therapeutics
Consulting or Advisory Role - Ferring; Photocure; QED Therapeutics; Taris
Research Funding - Photocure
Travel, Accommodations, Expenses - Janssen Oncology; Photocure
 
Ian M.
Employment - CHRISTUS Health; CHRISTUS Health
Leadership - H-E-B (grocery store chain)
Consulting or Advisory Role - Magforce
Research Funding - MagForce
Patents, Royalties, Other Intellectual Property - I have several patents with colleagues involving novel biomarkers for cancer and two devices for sexual dysfunction and urinary incontinence. No revenues at this time and our University IP office is working with industry to determine if these can be comme
 
Thomas W. Flaig
Leadership - Aurora Oncology; University of Colorado/UC Health
Stock and Other Ownership Interests - Aurora Oncology
Consulting or Advisory Role - Janssen Oncology; Seagen
Research Funding - Agensys; Aragon Pharmaceuticals; Astellas Pharma; astrazeneca/MedImmune; Bavarian Nordic; Bristol-Myers Squibb; Criterium; Dendreon; Exelixis; GTx; Janssen Oncology; La Roche-Posay; Lilly; Medivation; Merck; Myovant Sciences; Novartis; Pfizer; Roche/Genentech; Sanofi; Seagen; Seagen; Sotio; Tokai Pharmaceuticals
Patents, Royalties, Other Intellectual Property - The University of Colorado has filed 2 patents in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or in active clinical development right now (e.g. neither are in clinical trials).
 
Daniel P. Petrylak
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Gilead Sciences; Incyte; Ipsen; Janssen; Lilly; Mirati Therapeutics; Monopteros Therapeutics; Pfizer; Pharmacyclics; Regeneron; Roche; Seagen; Urogen pharma
Research Funding - Advanced Accelerator Applications (Inst); Agensys (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Endocyte (Inst); Genentech (Inst); Gilead Sciences (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Replimune (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Expert Testimony - Celgene; sanofi
 
Seth P. Lerner
Stock and Other Ownership Interests - Aura Biosciences; C2i genomics
Honoraria - Grand Rounds in Urology; UroToday
Consulting or Advisory Role - AstraZeneca; Aura Biosciences; Bristol-Myers Squibb Foundation/Janssen; C2i Genomics; Ferring; Pfizer/EMD Serono; Protara Therapeutics; Stimit; Vaxiion; Verity Pharmaceuticals
Research Funding - Endo Pharmaceuticals; FKD Therapies; Japan BCG Laboratory; QED Therapeutics; Roche/Genentech; Vaxiion; Viventia Biotech
Patents, Royalties, Other Intellectual Property - TCGA expression subtype singel patient classifier
Other Relationship - Bladder Cancer Journal; UpToDate